Pharmacology and Therapy for Liver Cirrhosis
Diagnosis and rationale for diagnosis
The diagnosis fora patient representing symptoms such as nausea, vomiting, and diarrhoea and has a history of drug abuse and possible Hepatitis C and currently taking Synthroid 100 mcg, Nifedipine 30 mg, and, Prednisone 10 mg prescriptions are primarily suffering from Cirrhosis of the Liver. Cirrhosis of the Liver is a chronic and progressive health issue arises due to the loss and illness of standard liver structure, causing liver failure (Osna et al., 2017). Even though further testing is needed to confirm my diagnosis based on symptoms and prescribed drugs, the rationale for my diagnosis is the likely causes of Cirrhosis of the liver which is viral hepatitis C infection and continuous drug abuse. Hepatitis C, which is not easily detected, irritates the stomach and intestine leading to symptoms such as diarrhoea, nausea and, vomiting, which affects the liver (Sakaida et al., 2017). Also, the current medication taken gives a hint of the illness. Therefore a combination of drug treatment, unhealthy lifestyles and, symptoms shows the patient is likely suffering from Gastroenteritis.
Drug therapy plan and its justification
To be able to manage liver damages, drug therapy medication such as Prednisone 10 mg daily to treat arthropathy infection due to Hepatitis C, Synthroid 100 mg acts as hormone replacement, and Nifedipine 30 mg daily treats acute liver damages (Kockerling et al., 2019). The used alcohol abuse treatment therapy prevents alcohol consumption which is a toxin which affects the ability of a liver to process and remove toxins from the bod. Abstinence from drug and alcohol consumption is hard for drug-dependent patients, therefore alcohol therapy treatment helps patients to stop drinking to protect the liver and enable the patient to live a hehttps://essaygroom.com/slide-1-2/althy life (Sinclair et al., 2016). The justification of alcohol therapy is to prevent sharing of needles when different people use the same needle to inject the drug, causing Hepatitis C, which damages the liver.
References
Kockerling, D., Nathwani, R., Forlano, R., Manousou, P., Mullish, B. H., & Dhar, A. (2019). Current and future pharmacological therapies for managing Cirrhosis and its complications. World Journal of Gastroenterology, 25(8), 888.
Osna, N. A., Donohue Jr, T. M., & Kharbanda, K. K. (2017). Alcoholic liver disease: Pathogenesis and current management. Alcohol research: current reviews, 38(2), 147.
Sakaida, I., Terai, S., Nakajima, K., Shibasaki, Y., Tachikawa, S., & Tsubouchi, H. (2017). Predictive factors of the pharmacological action of tolvaptan in patients with liver cirrhosis: a post hoc analysis. Journal of gastroenterology, 52(2), 229-236.
Sinclair, M., Gow, P. J., Grossmann, M., & Angus, P. W. (2016). sarcopenia in Cirrhosis–aetiology, implications and potential therapeutic interventions. Alimentary pharmacology & therapeutics, 43(7), 765-777.